VACCINES –
THE KEY PARADIGM FOR THE 21st CENTURY'S HEALTH CARE STRATEGY

THURSDAY, APRIL 28, 2011

15:00-15:40

WELCOME ADDRESS AND KEY NOTE LECTURE

Welcome address: Alexander von Gabain, MFPL of the University of Vienna, Chair of the SAB of Intercell, Vienna, Austria

Key note speaker: Martin Shuurmans, Chair of the Governing Board, European Institute of Innovation and Technology (EIT)
EIT: Create ecosystems that nurture new business creation for Europe

15:40-16:00

Coffee break

SESSION 1: Badly needed novel vaccines

16:00-16:20

Franz Xaver Heinz, University of Vienna, Institute of Virology, Vienna, Austria
Flaviviruses

16:20-16:40

Ginamarie Foglia, Sanofi Pasteur, Swiftwater, USA
C difficile

16:40-17:00

Peter Lawætt Andersen, Statens Serum Institut, Copenhagen, Denmark
TB Programs

17:00-17:20

Wayne C. Koff, International AIDS Vaccine Initiative, New York, USA
Challenges and opportunities in HIV vaccine development

17:20-18:00

Challenge panel:

Michael Pfleiderer, Paul Ehrlich Institute, Langen, Germany
Andrew Baum, Morgan Stanley & Co. International Limited, London, UK

18:00-19:00

OPENING POSTER SESSION AND GET TOGETHER

Opening Poster Session

19:00-

Dinner

FRIDAY, APRIL 29, 2011

SESSION 2: What vaccinologists expect from immunologists

08:30-08:50

Richard Malley, Harvard Medical School, Children’s Hospital, Boston, USA
Role of TH17 in the pneumococcal immune response

08:50-09:10

Giorgio Trinchieri, National Cancer Institute at Frederick, Frederick, USA
Regulation of adaptive immunity by NK cells

09:10-09:30

Jay A. Berzofsky, National Cancer Institute, Bethesda, USA
TLR ligands, cytokines, and the T cell response

09:30-09:50

Georg Stingl, General Hospital Vienna, Vienna, Austria
Different DCs – different functions

09:50-10:30

Challenge panel:            

Michael Pride, Pfizer Inc., Pearl River, New York, USA
Rino Rappuoli, Novartis Vaccines, Siena, Italy.
Thomas Decker, Max F. Perutz Laboratories, Vienna, Austria

10:30-11:00

Morning break

SESSION 3: About allergies, autoimmunity, microbes and vaccines

11:00-11:20

Andrew T. Gewirtz, Emory University, School of Medicine, Atlanta, USA
Innate immune regulation of gut microbiota and potential therapeutic opportunities to treat metabolic disease and chronic infections

11:20-11:40

Birgit Linhart, Medical University of Vienna, Vienna, Austria
A vaccine for the treatment of grass pollen allergy based on hypoallergenic hybrid molecules

11:40-12:00

Bengt Björkstén, Karolinska institute, Stockholm, Sweden
The Hygiene Hypothesis; Consequences for vaccine development

12:00-12:20

Peter Zerhouni, Diamyd Medicals, Stockholm, Sweden
A diabetes vaccine

12:20-13:00

Challenge panel:

Hans Wigzell, Karolinska Institute, Stockholm, Sweden
Philippe Moingeon, Stallergenes S.A., Antony Cedex, France

13:00-14:30

Lunch break

SESSION 4: Novel adjuvants – breakthroughs and setbacks,
where will we end?

14:30-14:50

Hermann Wagner, Technical University Munich, München, Germany
Adjuvants and innate immunity

14:50-15:10

Ozzie Berger, GlaxoSmithKline Biologicals, Wavre, Belgium
TLR-4: From research to registered vaccines

15:10-15:30

Derek O´Hagan, Novartis Vaccine and Diagnostics, Cambridge, USA
MF59

15:30-15:50

Veit Hornung, University Hospital Bonn, Bonn, Germany
Role of the inflammasome in adjuvanticity

15:50-16:10

Claire-Ann Siegrist, University of Geneva, Geneva, Switzerland
Neonatal immunization: which challenges for novel vaccines?

16:10-16:50

Challenge panel:

Steven G. Reed, IDRI - Infectious Disease Research Institute, Seattle, USA
Martin Friede, World Health Organization, Geneva, Switzerland
Sefik S. Alkan, Alkan Consulting LLC, Basel, Switzerland

16:50-18:30

Long afternoon break

18:30-19:15

AUSTRIAN EVENING

In the footsteps of The Third Man
- A cinematic and musical journey through Vienna
Rare and unusual filmic views of Vienna - presented by Michael Loebenstein
Famous Viennese zithermusic live and authentic in style - played by Cornelia Mayer

19:30-

Dinner 
Buffet with traditional Austrian food and live-cooking of “Kaiserschmarren” (Austrian dessert)

SATURDAY, APRIL 30, 2011

SESSION 5: Improving administration also for vaccines in the less developed world

08:30-08:50

Larry Ellingsworth, Intercell USA, Gaithersburg, USA
Patch technology

08:50-09:10

Martine Denis, Sanofi Pasteur, Marcy l’Etoile, France
Microneedle technology and its application to influenza vaccination by the intradermal route

09:10-09:30

Michael Royals, PharmaJet, Golden, Colorado, USA
Enhancing vaccination outcomes with an ID jet injection device

09:30-09:50

George Mutwiri, University of Saskatchewan, Saskatoon, Canada
PCPP-based microneedles

09:50-10:30

Challenge panel:

Maria Elena Bottazzi, The George Washington University, Washington, USA
Andreas Meinke, Intercell AG, Vienna, Austria
Christoph Klade, Intercell AG, Vienna, Austria

10:30-11:00

Morning break

SESSION 6: Quo vadis flu vaccines – learning from the H1N1 pandemic in the light of new technologies and established paradigms

11:00-11:20

Lone Simonsen, The George Washington University, Washington, USA
Signature features and health burden of the 2009 H1N1 pandemic and historic pandemics

11:20-11:40

Klaus Stöhr, Novartis Vaccines and Diagnostics, Cambridge, USA
Novel influenza vaccines: how will they meet health needs

11:40-12:00

Derek Smith, University of Cambridge, UK
The antigenic evolution of influenza virus

12:00-12:20

Gerald Aichinger, Baxter Innovations GmbH, Vienna, Austria
A cell culture flu vaccine

12:20-12:40

Thomas Hofstaetter, VaxInnate, Cranbury, USA
A simple approach to a flu vaccine

12:40-13:20

Challenge panel:     

John Oxford, Queen Mary School of Medicine, London, UK
Michael Perdue, U.S. Department of Health & Human Services, Washington, USA      

13:20-15:00

Lunch break

SESSION 7: Late breakers in vaccine development

15:00-15:20

Jessica Flechtner, Genocea Biosciences, Cambridge, USA
T cell vaccines

15:20-15:40

Michael Wacker, GlycoVaxyn AG, Schlieren, Switzerland
Paradigm shift in discovery and production of glycoconjugate vaccines

15:40-16:00

Robert Sims, Dendreon Corporation, Seattle, USA
Sipuleucel-T: Autologous cellular immunotherapy for prostate cancer

16:00-16:20

Maria Elena Bottazzi, The George Washington University, Washington, USA
Advances in the development of vaccines against neglected tropical diseases

16:20-16:40

Karl Josef ("Kajo") Kallen, CureVac GmbH, Tübingen, Germany
RNA-based vaccines: a new approach to immunization

16:40-17:00

Afternoon break

CONCLUDING PANEL DISCUSSION:

Need and acceptance of vaccines – how to deal with it?
Panel on the importance of vaccines for global health care and how to deal with fear

17:00-18:00

Stanley Plotkin, Consultant in Vaccinology, Doylestown, USA
Fred Zepp, Johannes Gutenberg University of Mainz, Germany
John Shiver, Merck & Co., Inc., West Point, USA
Thomas Szucs, European Center of Pharmaceutical Medicine, University of Basel, Switzerland
Shan Lu, University of Massachusetts Medical School, Worcester, USA

Chairman: Alexander von Gabain, MFPL of the University of Vienna, Chair of the SAB of Intercell, Vienna, Austria

19:00- …

CLOSING DINNER